Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Trillium Therapeutic (TRIL)

Trillium Therapeutic (TRIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,054,935
  • Shares Outstanding, K 103,021
  • Annual Sales, $ 150 K
  • Annual Income, $ -59,350 K
  • 60-Month Beta 2.02
  • Price/Sales 7,016.57
  • Price/Cash Flow N/A
  • Price/Book 3.86
Trade TRIL with:

Options Overview

Details
  • Implied Volatility 122.38%
  • Historical Volatility 65.13%
  • IV Percentile 39%
  • IV Rank 26.94%
  • IV High 212.66% on 04/20/20
  • IV Low 89.09% on 10/21/20
  • Put/Call Vol Ratio 0.10
  • Today's Volume 997
  • Volume Avg (30-Day) 1,322
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 30,507
  • Open Int (30-Day) 19,520

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.19
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.55 +7.23%
on 03/25/21
12.20 -16.07%
on 03/15/21
-1.79 (-14.88%)
since 03/12/21
3-Month
9.27 +10.45%
on 03/05/21
15.43 -33.64%
on 01/15/21
-4.73 (-31.60%)
since 01/14/21
52-Week
4.05 +152.84%
on 04/20/20
20.96 -51.15%
on 11/30/20
+5.34 (+108.98%)
since 04/14/20

Most Recent Stories

More News
December 17th Options Now Available For Trillium Therapeutics (TRIL)

Investors in Trillium Therapeutics Inc saw new options begin trading today, for the December 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

TRIL : 10.24 (+1.59%)
Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer

, /PRNewswire/ -- The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with...

TOMDF : 0.0548 (-3.86%)
AGEN : 2.69 (-0.74%)
LPTX : 1.7400 (+0.58%)
TRIL : 10.24 (+1.59%)
VSTM : 2.68 (-0.74%)
Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF)("" or the ""), a drug discovery and development company focused on developing next generation psilocybin and...

TRIL : 10.24 (+1.59%)
MSET.CN : 0.490 (-10.91%)
MSSTF : 0.3984 (-13.39%)
First Week of TRIL November 19th Options Trading

Investors in Trillium Therapeutics Inc saw new options begin trading this week, for the November 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...

TRIL : 10.24 (+1.59%)
Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including...

TRIL : 10.24 (+1.59%)
TRIL.TO : 12.82 (+1.34%)
Thinking about buying stock in IsoRay, Trillium Therapeutics, Plug Power, Baudax Bio, or Aslan Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISR, TRIL, PLUG, BXRX, and ASLN.

ISR : 1.0300 (-0.96%)
ASLN : 3.15 (+3.28%)
BXRX : 1.1300 (+2.73%)
PLUG : 28.39 (-3.07%)
TRIL : 10.24 (+1.59%)
Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development

Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("" or the ""), a biotechnology company focused on developing psychedelic...

TRIL : 10.24 (+1.59%)
ENBI.CN : 0.570 (-3.39%)
ENTBF : 0.4520 (-3.25%)
Continued Research Grants New Options in Cancer Treatment

, /PRNewswire/ -- The growing prevalence of cancer all over the globe is a major obstacle to overcome. In 2020, an estimated 1,806,590 new cases of cancer were diagnosed in alone and 606,520 people...

SBFM : 0.1230 (-6.96%)
CRDF : 8.80 (+2.80%)
TRIL : 10.24 (+1.59%)
SURF : 7.34 (+1.24%)
CTMX : 7.22 (+5.71%)
An Aging Population is Increasing the Need for Novel Treatments

, /PRNewswire/ -- With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size over the past...

MRNA : 160.03 (+6.89%)
BDSI : 3.46 (+0.29%)
VRTX : 217.13 (+0.55%)
TRIL.TO : 12.82 (+1.34%)
TRIL : 10.24 (+1.59%)
VPH.CN : 1.130 (+4.63%)
VPHIF : 0.8906 (+2.37%)
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

--New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology

PFE : 37.17 (+0.03%)
EPIX : 26.64 (-1.62%)
TRIL : 10.24 (+1.59%)
FIXX : 7.22 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin...

See More

Key Turning Points

3rd Resistance Point 11.10
2nd Resistance Point 10.89
1st Resistance Point 10.56
Last Price 10.24
1st Support Level 10.02
2nd Support Level 9.81
3rd Support Level 9.48

See More

52-Week High 20.96
Fibonacci 61.8% 14.50
Fibonacci 50% 12.50
Fibonacci 38.2% 10.51
Last Price 10.24
52-Week Low 4.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar